Entrada Therapeutics Announces Independent Data Monitoring Committee Review Of All Available Safety And PK Data From The Eight Participants Enrolled In Cohort 2 Of The Double-Blind, Placebo-Controlled, Multiple Ascending Dose Portion of ELEVATE-44-201

Entrada Therapeutics announced that the Independent Data Monitoring Committee (DMC) has reviewed safety and pharmacokinetic data from eight participants in Cohort 2 of the ELEVATE-44-201 study. The DMC recommended advancing to Cohort 3 with a top dose of 18 mg/kg, up from 12 mg/kg in Cohort 2 and 6 mg/kg in Cohort 1. This Phase 1/2 clinical study is focused on the treatment of Duchenne muscular dystrophy (DMD) for participants with a specific mutation in the DMD gene.